Jules Marc Fried Form 3 Bionik Laboratories / Jules Marc Fried ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Fried Jules Marc

(Last) (First) (Middle)

C/O INTERACTIVE MOTION TECHNOLOGIES, INC

80 COOLIDGE HILL ROAD

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/21/2016

3. Issuer Name and Ticker or Trading Symbol
Bionik Laboratories Corp. [ BNKL ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
VP - U.S. Operations

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value $0.001 per share	868,647(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	04/21/2016	06/02/2025	Common Stock, par value $0.001 per share	3,953	0.95	D
Employee Stock Option (Right to Buy)	04/21/2016	07/29/2025	Common Stock, par value $0.001 per share	906,077	0.25	D
Employee Stock Option (Right to Buy)	04/21/2016	06/02/2025	Common Stock, par value $0.001 per share	15,291	1.05	D
Employee Stock Option (Right to Buy)	04/21/2016	07/29/2025	Common Stock, par value $0.001 per share	671,857	0.95	D

Explanation of Responses:

1. 173,730 of such shares are held in escrow to satisfy potential indemnity claims under that certain Agreement and Plan of Merger dated March 1, 2016, by and among Bionik Laboratories Corp., Bionik Mergerco Inc., Hermano Igo Krebs and Interactive Motion Technologies, Inc.

	/s/ Jules Fried	04/27/2016
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.